Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: part 2. development of oral dosage formulations

References

• Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): a clinical review. Phytother Res. 2019;33(3):504–523.
   PubMed Web of Science ®Google Scholar
• Belwal T, Bisht A, Devkota HP, et al. Phytopharmacology and clinical updates of berberis species against diabetes and other metabolic diseases. Front Pharmacol. 2020;11:41.
   PubMed Web of Science ®Google Scholar
• Chitlange S, Kamble S, Deshkar S. Bioavailability of berberine: challenges and solutions. İ̇stanbul Journal of Pharmacy. 2021;51(1):141–153.
   Web of Science ®Google Scholar
• Liu YT, Hao HP, Xie HG, et al., Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos. 2010;38:1779–1784.
   PubMed Web of Science ®Google Scholar
• Chen W, Miao YQ, Fan DJ, et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS Pharm Sci Tech. 2011;12(2):705–711. DOI:10.1208/s12249-011-9632-z
   PubMed Web of Science ®Google Scholar
• Wang W, Shen Q, Liang H, et al. Pharmacokinetic studies of novel berberine derivatives with ultra-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1031:172–180.
   PubMed Web of Science ®Google Scholar
• Feng X, Wang K, Cao S, et al. Pharmacokinetics and excretion of berberine and its nine metabolites in rats. Front Pharmacol. 2021;11:594852.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tong Q, Shou JW, et al. Gut microbiota-mediated personalized treatment of hyperlipidemia using berberine. Theranostics. 2017;7(9):2443–2451. DOI:10.7150/thno.18290
   PubMed Web of Science ®Google Scholar
• Cui HX, Hu YN, Li JW, et al. Preparation and evaluation of antidiabetic agents of berberine organic acid salts for enhancing the bioavailability. Molecules. 2018;24(1):103.
   PubMed Web of Science ®Google Scholar
• Ma JY, Feng R, Tan XS, et al. Excretion of berberine and its metabolites in oral administration in rats. J Pharm Sci. 2013;102(11):4181–4192.
   PubMed Web of Science ®Google Scholar
• Yu C, Zhang H, Pan JF, et al. Determination and preliminary studies of metabolism of berberine in human urine after oral adminidtration. Chin J Clin Pharmacol. 2000;16:36–39.
   Google Scholar
• Cheng M, Liu R, Wu Y, et al. LC-MS/MS determination and urinary excretion study of seven alkaloids in healthy Chinese volunteers after oral administration of Shuanghua Baihe tablets. J Pharm Biomed Anal. 2016;118:89–95.
   PubMed Web of Science ®Google Scholar
• Ye M, Fu S, Pi R, et al. Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research. J Pharm Pharmacol. 2009;6(7):831–837. DOI:10.1211/jpp.61.07.0001
   Google Scholar
• Murakami T, Bodor E, Bodor N. Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: part 1. Physicochemical and pharmacokinetic properties. Expert Opin Drug Metab Toxicol. 2023;1-9. DOI: 10.1080/17425255.2023.2203857
   Web of Science ®Google Scholar
• Kaminsky LS, Fasco MJ. Small intestinal cytochromes P450. Crit Rev Toxicol. 1991;21(6):407–422.
   PubMed Web of Science ®Google Scholar
• Qiu F, Zhu Z, Kang N, et al. Isolation and identification of urinary metabolites of berberine in rats and humans. Drug Metab Dispos. 2008;36(11):2159–2165.
   PubMed Web of Science ®Google Scholar
• Miyazaki S, Oshiba M, Nadai T. Dissolution properties of salt forms of berberine. Chem Pharm Bull. 1981;29(3):883–886.
   Web of Science ®Google Scholar
• Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol. 2008;4(7):923–939.
   PubMed Web of Science ®Google Scholar
• Murakami T. Absorption sites of orally administered drugs in the small intestine. Expert Opin Drug Discov. 2017;12(12):1219–1232.
   PubMed Web of Science ®Google Scholar
• Maeng HJ, Yoo HJ, Kim IW, et al. P-Glycoprotein–mediated transport of berberine across Caco-2 cell monolayers. J Pharm Sci. 2002;91(12):2614–2621. DOI:10.1002/jps.10268
   PubMed Web of Science ®Google Scholar
• Najar IA, Sachin BS, Sharma SC, et al. Modulation of P-glycoprotein ATPase activity by some phytoconstituents. Phytother Res. 2010;24(3):454–458.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Hellum BH, Liang A, et al. The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetrahydropalmatine, neferine and berberine. Phytother Res. 2012;26(2):277–283. DOI:10.1002/ptr.3554
   PubMed Web of Science ®Google Scholar
• Brewster ME, Vandecruys R, Verreck G, et al. Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions. Pharmazie. 2008;63(3):217–220.
   PubMed Web of Science ®Google Scholar
• Brouwers J, Brewster ME, Augustijns P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci. 2009;98(8):2549–2572.
   PubMed Web of Science ®Google Scholar
• Bevernage J, Brouwers J, Brewster ME, et al. Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues. Int J Pharm. 2013;453(1):25–35. DOI:10.1016/j.ijpharm.2012.11.026
   PubMed Web of Science ®Google Scholar
• Jia J, Zhang K, Zhou X, et al. Zein/MCM-41 nanocomposite film incorporated with cinnamon essential oil loaded by modified supercritical CO2 impregnation for long-term antibacterial packaging. Pharmaceutics. 2020;12(2):169. DOI:10.3390/pharmaceutics12020169
   PubMed Web of Science ®Google Scholar
• Sahibzada MUK, Iqbal MJ, Sadiq A, et al. Berberine nanoparticles with enhanced in vitro bioavailability: characterization and antimicrobial activity. Drug Des Devel Ther. 2018;12:303–312.
   PubMed Web of Science ®Google Scholar
• Iversen TG, Skotlan T, Sandvig K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nanotoday. 2011;6(2):176–185.
   Google Scholar
• Varma S, Dey S, Palanisamy D. Cellular uptake pathways of nanoparticles: process of endocytosis andfactors affecting their fate. Curr Pharm Biotechnol. 2022;23(5):679–706.
   PubMed Web of Science ®Google Scholar
• Mazumdar S, Chitkara D, Mittal A. Exploration and insights into the cellular internalization and intracellular fate of amphiphilic polymeric nanocarriers. Acta Pharm Sin B. 2021;11(4):903–924.
   PubMed Web of Science ®Google Scholar
• Sut S, Faggian M, Baldan V, et al. Natural deep eutectic solvents (NADES) to enhance berberine absorption: an in vivo pharmacokinetic study. Molecules. 2017;22(11):1921. DOI:10.3390/molecules22111921
   PubMed Web of Science ®Google Scholar
• Xu HY, Liu CS, Huang CL, et al. Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge. Colloids Surf B Biointerfaces. 2019;181:927–934.
   PubMed Web of Science ®Google Scholar
• Feng R, Shou JW, Zhao ZX, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015;5(1):12155. DOI:10.1038/srep12155
   PubMedGoogle Scholar
• Zhang X, Qiu F, Jiang J, et al. Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein. Xenobiotica. 2011;41(4):290–296. DOI:10.3109/00498254.2010.529180
   PubMed Web of Science ®Google Scholar
• Shan YQ, Zhu YP, Pang J, et al. Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function. Biol Pharm Bull. 2013;36(10):1562–1569. DOI:10.1248/bpb.b13-00272
   PubMed Web of Science ®Google Scholar
• Uekama K, Arima H, Hirayama F. Involvement of cholesterol in the inhibitory effect of dimethyl-β-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett. 2003;536(1–3):225–231.
   PubMed Web of Science ®Google Scholar
• Arima H, Yunomae K, Morikawa T, et al. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-β-cyclodextrin on efflux function of p-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant caco-2 cell monolayers. Pharm Res. 2004;21(4):625–634. DOI:10.1023/B:PHAM.0000022409.27896.d4
   PubMed Web of Science ®Google Scholar
• Gurjar R, Chan CYS, Curley P, et al. Inhibitory effects of commonly used excipients on P-glycoprotein in vitro. Mol Pharm. 2018;15(11):4835–4842. DOI:10.1021/acs.molpharmaceut.8b00482
   PubMedGoogle Scholar
• Johnson BM, Charman WN, Porter CJ. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci. 2002;4(4):E40.
   PubMedGoogle Scholar
• Rao Z, Si L, Guan Y, et al. Inhibitive effect of cremophor RH40 or tween 80-based self-microemulsiflying drug delivery system on cytochrome P450 3A enzymes in murine hepatocytes. J Huazhong Univ Sci Technolog Med Sci. 2010;30(5):562–568. DOI:10.1007/s11596-010-0543-0
   PubMedGoogle Scholar
• Patel R, Barker J, Eishaer A. Pharmaceutical excipients and drug metabolism: a mini-review. Int J Mol Sci. 2020;21(21):8224.
   PubMed Web of Science ®Google Scholar
• Shen Q, Lin Y, Handa T, et al. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm. 2006;313(1–2):49–56. DOI:10.1016/j.ijpharm.2006.01.020
   PubMedGoogle Scholar
• Mudra DR, Borchardt RT. Absorption barriers in the rat intestinal mucosa. 3: effects of polyethoxylated solubilizing agents on drug permeation and metabolism. J Pharm Sci. 2010;99(2):1016–1027.
   PubMed Web of Science ®Google Scholar
• Ren X, Mao X, Cao L, et al. Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. Eur J Pharm Sci. 2009;36(4–5):401–411. DOI:10.1016/j.ejps.2008.11.002
   PubMed Web of Science ®Google Scholar
• Kwon M, Lim DY, Lee CH, et al. Enhanced intestinal absorption and pharmacokinetic modulation of berberine and its metabolites through the inhibition of P-glycoprotein and intestinal metabolism in rats using a berberine mixed micelle formulation. Pharmaceutics. 2020;12(9):882.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85(10):1017–1025.
   PubMed Web of Science ®Google Scholar
• Bodor N, Buchwald P. Theoretical insights into the formation, structure, and energetics of some cyclodextrin complexes. J Incl Phenom Macroc Chem. 2002;44(1/4):9–414.
   Web of Science ®Google Scholar
• Brewster ME, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev. 2007;59(7):645–666.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cui YL, Gao LN, et al. Effects of β-cyclodextrin on the intestinal absorption of berberine hydrochloride, a P-glycoprotein substrate. Int j biol macromol. 2013;59:363–371.
   PubMed Web of Science ®Google Scholar
• Yu JS, Wei FD, Gao W, et al. Thermodynamic study on the effects of β-cyclodextrin inclusion with berberine. Spectrochim Acta A Mol Biomol Spectrosc. 2002;58(2):249–256.
   PubMed Web of Science ®Google Scholar
• Chen XM, Chen Y, Hou XF, et al. Sulfonato-β-cyclodextrin mediated supramolecular nanoparticle for controlled release of berberine. ACS Appl Mater Interfaces. 2018;10(30):24987–24992. DOI:10.1021/acsami.8b08651
   PubMed Web of Science ®Google Scholar
• Ma S, Wang Y, Shang X, et al. Formulation of berberine hydrochloride and hydroxypropyl-β-Cyclodextrin INclusion Complex With Enhanced Dissolution And Reduced Bitterness. Trop J Pharm Res. 2012;11(6):871–877. DOI:10.4314/tjpr.v11i6.1
   Web of Science ®Google Scholar
• Mai Y, Dou L, Murdan S, et al. An animal’s sex influences the effects of the excipient PEG 400 on the intestinal P-gp protein and mRNA levels, which has implications for oral drug absorption. Eur J Pharm Sci. 2018;120:53–60.
   PubMed Web of Science ®Google Scholar
• Wang T, Wang N, Song H, et al. Preparation of an anhydrous reverse micelle delivery system to enhance oral bioavailability and anti-diabetic efficacy of berberine. Eur J Pharm Sci. 2011;44(1–2):127–135. DOI:10.1016/j.ejps.2011.06.015
   PubMed Web of Science ®Google Scholar
• Kang H, Yao Y, Zhang X. Mixed micelles with galactose ligands for the oral delivery of berberine to enhance its bioavailability and hypoglycemic effects. J Biomed Nanotechnol. 2020;16(12):1755–1764.
   PubMed Web of Science ®Google Scholar
• Kwon M, Sang W, Linghu KG, et al. Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine. Int J Nanomedicine. 2018;13:3781–3793.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen Y, Deng J, et al. Solid dispersion of berberine–phospholipid complex/TPGS 1000/SiO2: preparation, characterization and in vivo studies. Int J Pharm. 2014;465(1–2):306–316. DOI:10.1016/j.ijpharm.2014.01.023
   PubMed Web of Science ®Google Scholar
• Zhang ZH, Sun YS, Pang H, et al. Preparation and evaluation of berberine alginate beads for stomach-specific delivery. Molecules. 2011;16(12):10347–10356. DOI:10.3390/molecules161210347
   PubMed Web of Science ®Google Scholar
• Ji J, He X, Yang XL, et al. The in vitro/vivo evaluation of prepared gastric floating tablets of berberine hydrochloride. AAPS Pharm Sci Tech. 2017;18(6):2149–2156. DOI:10.1208/s12249-016-0696-7
   PubMed Web of Science ®Google Scholar
• Mishra R, Dhole S. Lipid-based floating multiparticulate delivery system for bioavailability enhancement of berberine hydrochloride. J Applied Pharm Sci. 2019;9:036–047.
   Google Scholar
• Tang X, Yang M, Gu Y, et al. Orally deliverable dual-targeted pellets for the synergistic treatment of ulcerative colitis. Drug Des Devel Ther. 2021;15:4105–4123.
   PubMed Web of Science ®Google Scholar
• Murakami T, Bodor E, Bodor N. Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drug. Expert Opin Drug Metab Toxicol. 2021;17(5):555–580.
   PubMed Web of Science ®Google Scholar
• Savla R, Browne J, Plassat V, et al. Review and analysis of FDA approved drugs using lipid-based formulations. Drug Develop Ind Pharm. 2017;43(11):1743–1758. DOI:10.1080/03639045.2017.1342654
   PubMed Web of Science ®Google Scholar
• Yeap YY, Trevaskis NL, Quach T, et al. Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation. Mol Pharm. 2013;10(5):1874–1889. DOI:10.1021/mp3006566
   PubMedGoogle Scholar
• Li J, Yang L, Shen R, et al. Self-nanoemulsifying system improves oral absorption and enhances anti-acute myeloid leukemia activity of berberine. J Nanobiotechnology. 2018;16(1):76. DOI:10.1186/s12951-018-0402-x
   PubMedGoogle Scholar
• Zhu JX, Tang D, Feng L, et al. Development of self-microemulsifying drug delivery system for oral bioavailability enhancement of berberine hydrochloride. Drug Dev Ind Pharm. 2013;39(3):499–506. DOI:10.3109/03639045.2012.683875
   PubMed Web of Science ®Google Scholar
• Murakami T, Sasaki Y, Yamajo R, et al. Effect of bile salts on the rectal absorption of sodium ampicillin in rats. Chem Pharm Bull (Tokyo). 1984;32(5):1948–1955.
   PubMed Web of Science ®Google Scholar
• Nishimura K, Nozaki Y, Yoshimi A, et al. Studies on the promoting effects of carboxylic acid derivatives on the rectal absorption of .BETA.-lactam antibiotics in rats. Chem Pharm Bull (Tokyo). 1985;33(1):282–291. DOI:10.1248/cpb.33.282
   PubMed Web of Science ®Google Scholar
• Murakami T, Misaki M, Kojima Y, et al. Effect of absorption promoters on subcutaneous absorption of human epidermal growth factor in rats. J Pharm Sci. 1993;82(3):236–239. DOI:10.1002/jps.2600820303
   PubMed Web of Science ®Google Scholar
• Aungst BJ, Rogers NJ, Shefter E. Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter. J Pharmacol Exp Ther. 1988;244(1):23–27.
   PubMed Web of Science ®Google Scholar
• Tillman LG, Geary RS, Hardee GE. Oral delivery of antisense oligonucleotides in man. J Pharm Sci. 2008;97(1):225–236.
   PubMed Web of Science ®Google Scholar
• Twarog C, Fattah S, Heade J, et al. Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C10). Pharmaceutics. 2019;11(2):78.
   PubMed Web of Science ®Google Scholar
• Berg S, Kärrber GL, Suljovic D, et al. Impact of intestinal concentration and colloidal structure on the permeation-enhancing efficiency of sodium caprate in the rat. Mol Pharm. 2022;19(1):200–212.
   PubMedGoogle Scholar
• Lv XY, Li J, Zhang M, et al. Enhancement of sodium caprate on intestine absorption and antidiabetic action of berberine. AAPS Pharm Sci Tech. 2010;11(1):372–382. DOI:10.1208/s12249-010-9386-z
   PubMed Web of Science ®Google Scholar
• Fan D, Wu X, Dong W, et al. Enhancement by sodium caprate and sodium deoxycholate of the gastrointestinal absorption of berberine chloride in rats. Drug Dev Ind Pharm. 2013;39(9):1447–1456.
   PubMed Web of Science ®Google Scholar
• Zhaojie M, Ming Z, Shengnan W, et al. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability. Int J Pharm. 2014;467(1–2):50–59. DOI:10.1016/j.ijpharm.2014.03.017
   PubMed Web of Science ®Google Scholar
• Li Y, Liu F, Li Z, et al. Enhanced anti-diabetic effect of berberine combined with timosaponin B2 in Goto-Kakizaki rats, associated with increased variety and exposure of effective substances through intestinal absorption. Front Pharmacol. 2019;10:19.
   PubMed Web of Science ®Google Scholar
• Takács-Novák K, Szász G. Ion-pair partition of quaternary ammonium drugs: the influence of counter ions of different lipophilicity, size, and flexibility. Pharm Res. 1999;16(10):1633–1638.
   PubMed Web of Science ®Google Scholar
• Pavlović N, Goločorbin-Kon S, Ðanić M, et al. Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles. Front Pharmacol. 2018;9:1283.
   PubMed Web of Science ®Google Scholar
• Elsheikh MA, Elnaggar YSR, Hamdy DA, et al. Novel cremochylomicrons for improved oral bioavailability of the antineoplastic phytomedicine berberine chloride: optimization and pharmacokinetics. Int J Pharm. 2018;535(1–2):316–324. 41. Zhang X, Han Y, Huang W, et al. The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharm Sin B. 2021;11:1789-1812. DOI:10.1016/j.ijpharm.2017.11.023
   PubMed Web of Science ®Google Scholar
• Ryšánek P, Grus T, Šíma M, et al. Lymphatic transport of drugs after intestinal absorption: impact of drug formulation and physicochemical properties. Pharm Res. 2020;37(9):166. DOI:10.1007/s11095-020-02858-0
   PubMed Web of Science ®Google Scholar
• Porru E, Franco P, Calabria D, et al. Combined analytical approaches to define biodistribution and biological activity of semi-synthetic berberrubine, the active metabolite of natural berberine. Anal Bioanal Chem. 2018;410(15):3533–3545. DOI:10.1007/s00216-018-0884-2
   PubMed Web of Science ®Google Scholar
• Chae HW, Kim IW, Jin HE, et al. Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine. Arch Pharm Res. 2008;31(1):103–110. DOI:10.1007/s12272-008-1127-4
   PubMed Web of Science ®Google Scholar
• Yu F, Li Y, Chen Q, et al. Monodisperse microparticles loaded with the self-assembled berberine-phospholipid complex-based phytosomes for improving oral bioavailability and enhancing hypoglycemic efficiency. Eur J Pharm Biopharm. 2016;103:136–148.
   PubMed Web of Science ®Google Scholar
• Sen S, Paul BK, Guchhait N. Differential interaction behaviors of an alkaloid drug berberine with various bile salts. J Colloid Interface Sci. 2017;505:266–277.
   PubMed Web of Science ®Google Scholar
• Torky AS, Freag MS, Nasra MMA, et al. Novel skin penetrating berberine oleate complex capitalizing on hydrophobic ion pairing approach. Int J Pharm. 2018;549(1–2):76–86. DOI:10.1016/j.ijpharm.2018.07.051
   PubMedGoogle Scholar
• Stoyanova N, Ignatova M, Manolova N, et al. Nanoparticles based on complex of berberine chloride and polymethacrylic or polyacrylic acid with antioxidant and in vitro antitumor activities. Int J Pharm. 2020;584:119426.
   PubMedGoogle Scholar
• Gao Z, Liu S, Sun CC. Complexation with aromatic carboxylic acids expands the solid-state landscape of berberine. Int J Pharm. 2022;617:121587.
   PubMedGoogle Scholar
• Bakshi J, Lathar P, Mehra M, et al. Evaluation of anti-inflammatory response of berberine-loaded gum nanocomplexes in carrageenan-induced acute paw edema in rats. Pharmacol Rep. 2022;74(2):392–405. DOI:10.1007/s43440-021-00350-z
   PubMed Web of Science ®Google Scholar
• Li Z, Liu Y, Wang J, et al. Baicalin-berberine complex nanocrystals orally promote the co-absorption of two components. Drug Deliv Transl Res. 2022;12(12):3017–3028. DOI:10.1007/s13346-022-01167-w
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhao Y, Tan L, et al. A novel berberine-glycyrrhizic acid complex formulation enhanced the prevention effect to doxorubicin-induced cardiotoxicity by pharmacokinetic modulation of berberine in rats. Front Pharmacol. 2022;13:891829.
   PubMed Web of Science ®Google Scholar
• Lagona J, Mukhopadhyay P, Chakrabarti S. The cucurbit[n]uril family. Angew Chem Int Ed Engl. 2005;44(31):4844–4870.
   PubMed Web of Science ®Google Scholar
• Kim K, Selvapalam N, Ko YH, et al. Functionalized cucurbiturils and their applications. Chem Soc Rev. 2007;36(2):267–279. DOI:10.1039/B603088M
   PubMed Web of Science ®Google Scholar
• Miskolczy Z, Biczók L. Kinetics and thermodynamics of berberine inclusion in cucurbit[7]uril. J Phys Chem B. 2014;118(9):2499–2505.
   PubMed Web of Science ®Google Scholar
• Guo J, Han X, Wang S, et al. A cucurbit[6]uril based supramolecular assembly for the detection and removal of dyes and antibiotics from water. Anal Methods. 2022;14(26):2642–2648. DOI:10.1039/D2AY00658H
   PubMed Web of Science ®Google Scholar
• Dong N, Cheng LN, Wang XL, et al. Significant fluorescence enhancement by supramolecular complex formation between berberine chloride and cucurbit(n=7)uril and its analytical application. Talanta. 2011;84(3):684–689. DOI:10.1016/j.talanta.2011.01.071
   PubMed Web of Science ®Google Scholar
• Ji QT, Hu DK, Mu XF, et al. Cucurbit[7]uril-mediated supramolecular bactericidal nanoparticles: their assembly process, controlled release, and safe treatment of intractable plant bacterial diseases. Nano Lett. 2022;22(12):4839–4847. DOI:10.1021/acs.nanolett.2c01203
   PubMed Web of Science ®Google Scholar
• Wang K, Feng X, Chai L, et al. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev. 2017;49(2):139–157. DOI:10.1080/03602532.2017.1306544
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu W, Han F, et al. LC/MS/MS for identification of in vivo and in vitro metabolites of jatrorrhizine. Biomed Chromatogr. 2008;22(12):1360–1367. DOI:10.1002/bmc.1066
   PubMed Web of Science ®Google Scholar
• Wang X, Wang S, Ma J, et al. Pharmacokinetics in rats and tissue distribution in mouse of berberrubine by UPLC-MS/MS. J Pharm Biomed Anal. 2015;115:368–374.
   PubMed Web of Science ®Google Scholar
• Bodor N, Brewster ME. Lmproved delivery through biological membranes XV - Sustained brain delivery of berberine. Eur J Med Chem. 1983;18:235–240.
   Web of Science ®Google Scholar
• Brewster ME, Bodor N. Improved delivery through biological membranes XVI. Enhancement of the brain-specificity of a dihydropyridine formed from pyridinium salt drug delivery system by controlled infusion. J Parenter Sci Technol. 1983;37(5):159–164.
   PubMedGoogle Scholar
• Bodor N, Farag HG, Brewster ME 3rd. Site-specific, sustained release of drugs to the brain. Science. 1981;214(4527):1370–1372.
   PubMed Web of Science ®Google Scholar
• Moon JM, Ratliff KM, Hagele AM, et al. Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: a randomized, controlled, crossover pilot trial. Nutrients. 2021;14(1):124. DOI:10.3390/nu14010124
   PubMed Web of Science ®Google Scholar